Welcome to our dedicated page for TC BioPharm (Holdings) plc American Depositary Shares news (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) plc American Depositary Shares stock.
TC BioPharm (Holdings) PLC (NASDAQ: TCBP) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative immunotherapy products. The company leverages its proprietary allogeneic gamma-delta T (GD-T) cell platform to create novel therapies aimed at treating cancer and viral infections.
Gamma-delta T cells are unique immune cells that possess characteristics of both the innate and adaptive immune systems, enabling them to distinguish between healthy and diseased tissues. TC BioPharm's approach uses these cells to develop effective treatments for various cancers, including both liquid and solid tumors.
Notable achievements include the initiation of phase 2b/3 pivotal trials for OmnImmune® in the treatment of acute myeloid leukemia (AML) using their proprietary allogeneic CryoTC technology, which allows for the distribution of frozen cell products to clinics worldwide. The company also maintains a robust pipeline targeting solid tumors and has built a significant intellectual property portfolio.
Recent developments highlight TC BioPharm's dynamic progress:
- March 1, 2024: CEO Bryan Kobel featured on 'The Big Biz Show,' discussing the company's ongoing advancements.
- March 18, 2024: An institutional investor exercised warrants resulting in a net cash infusion of $1.17M, strengthening the company’s financial position.
- March 19, 2024: The company adjourned its General Meeting to gather additional information for a shareholder vote.
- April 2, 2024: Announcement of a new streamlined manufacturing process to increase patient treatment capacity and reduce costs by 85%.
- April 4, 2024: Execution of a non-binding letter of intent to acquire assets focused on CAR-NK cell therapies, enhancing their cancer treatment capabilities.
- May 6, 2024: Agreement for the immediate exercise of certain warrants, raising approximately £3.1M for clinical trials and operations.
- May 6, 2024: Announcement of a second letter of intent to acquire a company developing CAR-T therapies for solid tumors and autoimmune diseases.
- May 15, 2024: Launch of a compassionate use program in the UK for TCB-008, providing new treatment options for patients ineligible for clinical trials.
TC BioPharm continues to focus on expanding its therapeutic platform, leveraging strategic partnerships, and advancing its clinical trials, all while upholding its commitment to improving patient outcomes.
Rhea-AI Summary
TC BioPharm (Holdings) PLC (NASDAQ: TCBP) has received FDA clearance for its investigational new drug (IND) application for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML). The Phase 1B study, ACHIEVE2, will evaluate the safety, persistence/expansion, and preliminary efficacy of single and multiple IV doses of TCB008 in patients with AML or MDS/AML. The company also plans to continue the UK ACHIEVE trial in AML and submit amendments to the protocol to align with the ACHIEVE2 trial of TCBP's lead product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.53%
Tags
-
Rhea-AI Summary
TC BioPharm (NASDAQ: TCBP) Completes Safety Cohort for ACHIEVE Trial with Positive Review from DSMB. Management to Expand Trial in Q1 and Propose Protocol Amendments. Positive Safety Review Marks Milestone in Development of Allogeneic Gamma Delta Platform for Acute Myeloid Leukemia Treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.74%
Tags
-
Rhea-AI Summary
TC BioPharm has selected Fortrea as its Contract Research Organization (CRO) for global trials, including ACHIEVE and ACHIEVE2. The trials will be managed by Fortrea, creating a vertically integrated clinical trial program that aims to increase operational efficiencies and improve data management. TC BioPharm expects to generate cash savings by consolidating CRO services under a single entity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
News
Rhea-AI Summary
TC BioPharm selects Excellos as a partner for its US clinical trial efforts. Excellos will provide allogeneic cell banks to bridge donor blood with the final product. The partnership aims to enhance clinical trial success and optimize the final product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
-
Rhea-AI Summary
TC BioPharm submits an Investigational New Drug (IND) application for TCB-008 in the treatment of relapse/refractory Acute Myeloid Leukemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
-
Rhea-AI Summary
TC BioPharm to present at LD Micro Main Event conference on October 3-5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
News
Rhea-AI Summary
TC BioPharm has entered into a collaboration agreement with Queen Mary University of London to research the therapeutic potential of gamma-delta T cells for the treatment of mucosal infections. The collaboration received grant funding from The Impact Fund arm of QMUL. TC BioPharm will be working with Dr. Neil McCarthy's lab at QMUL. The project is financed by The Queen Mary Impact Fund and aims to understand how gamma-delta T-cell function can be restored by novel immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
-
Rhea-AI Summary
TC BioPharm regains compliance with Nasdaq Stock Market Listing Rule 5550(b)(2), maintaining listing on Nasdaq Global Select Market. The company had previously received a letter indicating non-compliance with the minimum Market Value of Listed Securities requirement. TC BioPharm submitted a plan to regain compliance and has now been notified of regaining compliance with shareholder equity concerns. The company will be subject to a Mandatory Panel Monitor for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.73%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.35%
Tags
Rhea-AI Summary
TC BioPharm (Holdings) PLC, a clinical stage biotechnology company, will be presenting at the LD Micro Invitational XIII Conference in Los Angeles, CA from June 6 - 8, 2023. The presentation will be held on June 7, 2023 at 2:00 pm ET. TC BioPharm CEO, Bryan Kobel, will be speaking at the conference. For more information or to schedule a meeting, please contact ir@tcbiopharm.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
FAQ
What is the current stock price of TC BioPharm (Holdings) plc American Depositary Shares (TCBP)?
The current stock price of TC BioPharm (Holdings) plc American Depositary Shares (TCBP) is $0.6239 as of November 22, 2024.
What is the market cap of TC BioPharm (Holdings) plc American Depositary Shares (TCBP)?
The market cap of TC BioPharm (Holdings) plc American Depositary Shares (TCBP) is approximately 343.8K.
What does TC BioPharm (Holdings) PLC specialize in?
TC BioPharm specializes in developing allogeneic gamma-delta T cell therapies for treating various cancers and viral infections.
What are gamma-delta T cells?
Gamma-delta T cells are immune cells that combine properties of the innate and adaptive immune systems, allowing them to effectively identify and target diseased tissues.
What is OmnImmune®?
OmnImmune® is TC BioPharm's therapeutic product currently in phase 2b/3 pivotal trials for treating acute myeloid leukemia (AML) using their proprietary allogeneic CryoTC technology.
How does TC BioPharm's CryoTC technology work?
CryoTC technology enables the company to freeze and distribute allogeneic gamma-delta T cell products to clinics worldwide, ensuring accessibility and efficacy.
What recent financial milestones has TC BioPharm achieved?
An institutional investor recently exercised warrants, providing a net cash infusion of $1.17M. Additionally, the company raised approximately £3.1M through the immediate exercise of certain outstanding warrants.
What new manufacturing initiatives has TC BioPharm announced?
TC BioPharm is developing a new manufacturing process expected to increase treatment capacity from 52 to over 1,000 patients per year while reducing costs by 85%.
What is TC BioPharm's compassionate use program?
The compassionate use program in the UK allows patients who are ineligible for clinical trials to access TC BioPharm's lead therapeutic TCB-008.
What are the company's latest strategic acquisitions?
TC BioPharm has executed non-binding letters of intent to acquire assets focused on CAR-NK cell therapies and a company developing CAR-T therapies for solid tumors and autoimmune diseases.
Where can I watch the CEO's interview on 'The Big Biz Show'?
The interview can be viewed on streaming services like Roku, iHeart Radio, and Apple Podcasts, among others.
What is TC BioPharm's position in the biopharmaceutical industry?
TC BioPharm is a leader in developing gamma-delta T cell therapies and the first to conduct phase II/pivotal clinical studies in oncology.
TC BioPharm (Holdings) plc American Depositary Shares
Nasdaq:TCBP
TCBP Rankings
TCBP Stock Data
343.79k
528.45k
0.01%
1.76%
11.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States of America
HOLYTOWN